Intravenous anti–IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis

Rothenberg, Marc E.; Wen, Ting; Greenberg, Allison; Alpan, Oral; Enav, Benjamin; Hirano, Ikuo; Nadeau, Kari; Kaiser, Sérgio; Peters, Thomas; Perez, Antonio; Jones, Ieuan; Jonathan, P.; Strieter, Robert M.; Sabo, Ronald; Gunawardena, K A

doi:10.1016/j.jaci.2014.07.049

Cited by 275 publications

(211 citation statements)

References 36 publications

Supporting

Mentioning

194

Contrasting

Unclassified

Order By: Relevance

“…Et donc ces molécules ont été sélectionnées comme les premiers candidats potentiels pour développer de nouvelles thérapies de l'EoE, notamment à partir de modèles animaux prometteurs [33,34,31,35]. En revanche, il n'a pas encore été démontré que des anticorps anti-IL-5 ou anti-IL-13 utilisésc hez des patients souffrant d'EoE pouvaient entraîner un bénéfice clinique, malgré quelques signes positifs dans des études préliminaires [36,37], alors même que l'anti-IL-5 utilisé (mepolizumab) ar e ç uu na grément aux USAp our traiter l'asthme sévère. On peut émettre l'hypothèse que ces molécules, essentiellement liées à la biologie des Th2 et des éosinophiles, jouent un rôle important dans l'EoE mais que celui-ci est redondant à cause d'autres mécanismes pathogéniques encore moins bien décrits.…”

Section: Etiologie Et Pathogénieunclassified

La mystérieuse œsophagite à éosinophiles garde encore quelques secrets

Vicari¹

2017

HEGEL

View full text Add to dashboard Cite

Section: Etiologie Et Pathogénieunclassified

La mystérieuse œsophagite à éosinophiles garde encore quelques secrets

Vicari¹

2017

HEGEL

View full text Add to dashboard Cite

“…A small case series of 3 adults showed some clinical and histological response with 6-mercaptopurine/azathioprine [113]. Another drug targeting the Prostagladin D2 receptor has showed small but significant improvement in the histology of EoE patients in a randomized prospective placebo controlled trial of 26 adults [114].…”

Section: Other Medical Treatments Including Disease Modifying Agentsmentioning

confidence: 99%

Eosinophilic Esophagitis: A Comprehensive Review

Nt¹

2016

J Hepatol Gastroint Dis

View full text Add to dashboard Cite

Eosinophilic Esophagitis (EoE) has been the subject of intense research and study over the past few years, as incidence and prevalence has increased in the United States, especially in adults. The signs, symptoms and complications of EoE arise from a complex interplay of genetic predisposition and environmental exposure that is not understood well at this time. The disease causes significant morbidity in both physical and psychological areas, and these effects may become permanent in some cases where remodeling of the epithelium is present. Treatment at this time mainly focuses on diet, medication and endoscopic dilation. While none of these entities can accomplish all of the treatment goals, careful selection of patients based on symptoms and physical findings can alleviate many of the complications of the disease. In addition, this review attempts to cull data from adult studies if possible, as much of the studies that involved children did not translate well to adult patients.

show abstract

“…In a study of 25 patients who were randomized to anti IL-13 antibody (QAX576) and placebo, there was histological and symptomatic, but statistically non-significant benefit with anti -IL13 antibody. 127 Further data is needed before this agent can be used in treatment of EoE. CRTH2 antagonist: CRTH2 (Chemoattractant receptor homologous molecule expressed on TH2 cells) is a prostaglandin D2 receptor, implicated in various allergic diseases.…”

Section: Investigational Agentsmentioning

confidence: 99%

Eosinophilic esophagitis

Kedia¹

2015

View full text Add to dashboard Cite

Eosinophilic esophagitis (EoE) is a clinico-pathological entity characterised by symptoms of esophageal dysfunction and eosinophilia on esophageal mucosal biopsies in the absence of other causes of esophageal eosinophilia. It is a chronic inflammatory condition of esophagus often characterized by refractory reflux symptoms in children and dysphagia in adults. It occurs as a result of Th2 inflammatory response to environmental triggers (food antigens) in genetically predisposed individuals. The diagnostic criteria include symptoms of esophageal dysfunction, esophageal eosinophilia (> 15/hpf), and a PPI trial (persistent eosinophilia after 8 weeks of PPI). Mainstay of treatment at present is topical steroids and dietary therapy.Maintenance treatment should be considered to prevent long term complications.

show abstract

Intravenous anti–IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis

Cited by 275 publications

References 36 publications

La mystérieuse œsophagite à éosinophiles garde encore quelques secrets

La mystérieuse œsophagite à éosinophiles garde encore quelques secrets

Eosinophilic Esophagitis: A Comprehensive Review

Eosinophilic esophagitis

Contact Info

Product

Resources

About